ARTICLE SUMMARY:
Patients with lung cancer are not well served by the current diagnostic model, which often puts them through months of years of anxious “watchful waiting” in the form of repeated imaging and diagnostic exams before the definitive but risky step of lung biopsy. ProLung hopes to change this paradigm with a front-end predictive analytic that’s adjunctive to the first low-dose computed tomography screen.
Lung cancer has the lowest survival rate of any cancers—17% at five years—largely because it is generally detected at such a late stage as to be incurable.
